Evidence map›Paper›PMID 38994114›Full record

ArticleHeliyon2024

Low protein expression of LZTR1 in hepatocellular carcinoma triggers tumorigenesis

Ganghui Ye, Jie Wang, Jingyi Xia, Chenlu Zhu, Chaoyu Gu, Xinming Li, Jingyun Li, Meng Ye, Xiaofeng Jin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Ubiquitination in hepatocellular carcinoma immunity.Journal of translational medicine · 2025
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ganghui YeDepartment of Biochemistry and Molecular Biology, Health Science Center, Ningbo University, Ningbo, 315211, China.
Jie WangDepartment of Biochemistry and Molecular Biology, Health Science Center, Ningbo University, Ningbo, 315211, China.
Jingyi XiaZhejiang Key Laboratory of Pathophysiology, Department of Biochemistry and Molecular Biology, Health Science Center of Ningbo University, Ningbo, 315211, China.
Chenlu ZhuZhejiang Key Laboratory of Pathophysiology, Department of Biochemistry and Molecular Biology, Health Science Center of Ningbo University, Ningbo, 315211, China.
Chaoyu GuDepartment of Oncology, The First Hospital of Ningbo University, Ningbo, 315020, China.
Xinming LiDepartment of Oncology, The First Hospital of Ningbo University, Ningbo, 315020, China.
Jingyun LiDepartment of Biochemistry and Molecular Biology, Health Science Center, Ningbo University, Ningbo, 315211, China.
Meng YeDepartment of Biochemistry and Molecular Biology, Health Science Center, Ningbo University, Ningbo, 315211, China.
Xiaofeng JinDepartment of Biochemistry and Molecular Biology, Health Science Center, Ningbo University, Ningbo, 315211, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

LZTR1 is a substrate specific adaptor for E3 ligase involved in the ubiquitination and degradation of RAS GTPases, which inhibits the RAS/RAF/MEK/ERK signaling to suppress the pathogenesis of Noonan syndrome and glioblastoma. However, it's still unknown whether LZTR1 destabilizes RAS GTPases to suppress HCC progression by inhibiting these signaling pathway. Lenvatinib is the first-line drug for the treatment of advanced HCC, however, it has high drug resistance. To explore the roles of LZTR1 in HCC progression and the underlying mechanisms of lenvatinib resistance, techniques such as bioinformatics analysis, immunohistochemical staining, RT-qPCR, Western blot, cell functional experiments, small interfering RNA transfection and cycloheximide chase assay were applied in our study. Among these, bioinformatics analysis and immunohistochemical staining results indicated that LZTR1 protein was aberrantly expressed at low levels in HCC tissues, and low protein expression of LZTR1 was associated with poor prognosis of HCC patients.

Indexed as

DegradationDrug resistanceHepatocellular carcinomaKRASLenvatinibLZTR1

Identifiers

PMID38994114
PMCPMC11237970

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.